Clinical Trials
137 trialsNCT03903562 2026-04-06
V503-024
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05119855 2026-02-05
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04210336 2025-12-18
PAPILOCAN
Procare Health Iberia S.L.
Phase NA Completed
NCT04607850 2025-08-28
Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions
Barinthus Biotherapeutics
Phase 1/2 Completed
NCT04772534 2025-05-30
V503-066
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04528407 2025-02-13
BS-FU01 Follow-Up Study of FluBHPVE6E7 Study Subjects
BlueSky Immunotherapies GmbH
Completed
NCT03487549 2024-11-27
COVE-1
Verrica Pharmaceuticals Inc.
Phase 2 Completed
NCT03981822 2024-11-27
CARE-1
Verrica Pharmaceuticals Inc.
Phase 2 Completed
NCT04199078 2024-10-31
PALOMA2
Procare Health Iberia S.L.
Phase NA Completed
NCT04472377 2024-10-03
HPV Typing Between Self- and Physician-sampled
Hygeia Touch Inc.
Phase NA Completed
NCT06439433 2024-06-03
ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase 2 Completed
NCT06399341 2024-05-03
PAPILOBSGR
Elpen Pharmaceutical Co. Inc.
Completed
NCT05679141 2024-04-26
Clinical Correlation Between Self-collected and Physician-collected HPV Screening Kits
Switch Health Solutions Inc.
Completed
NCT02634190 2024-02-28
Clinical Evaluation of the APTIMA® HPV Assay and Comparison With the HR HC2® Test Using LBC ThinPrep® Specimens
Hologic Deutschland GmbH
Completed
NCT06199128 2024-01-10
Fix
Uriach Consumer Healthcare
Completed
NCT05372016 2023-11-24
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd.
Phase 3 Completed
NCT06111911 2023-11-01
Detection of High-Risk HPV in Urine and Cervical Swab Specimen Using HPV Diagnostic Kit (Bio Farma)
PT Bio Farma
Phase NA Completed
NCT04490512 2023-06-26
Study of FluBHPVE6E7 in HPV-16 Infected Women
BlueSky Immunotherapies GmbH
Phase 1 Completed
NCT00380367 2023-05-31
Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03900572 2023-04-13
A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine
Shanghai Zerun Biotechnology Co.,Ltd
Phase 1 Completed
NCT04965350 2023-04-13
Lot Consistency Clinical Trial of Bivalent HPV Vaccine in 9 to 30 Years Old Healthy Females
Shanghai Zerun Biotechnology Co.,Ltd
Phase 3 Completed
NCT05694728 2023-01-23
A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine
Beijing Health Guard Biotechnology, Inc
Phase 2 Completed
NCT05680454 2023-01-17
A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine
Beijing Health Guard Biotechnology, Inc
Phase 1 Completed
NCT00943722 2022-10-03
A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01077856 2022-09-13
VIP
Merck Sharp & Dohme LLC
Completed
NCT01567813 2022-07-22
Post-Licensure Study of the Safety of GARDASIL™ in Males (V501-070)
Merck Sharp & Dohme LLC
Completed
NCT05426148 2022-06-29
Lot Consistency Clinical Trial of of Recombinant HPV Bivalent Vaccine in 9 to14 Years Old Healthy Female
Xiamen Innovax Biotech Co., Ltd
Phase 4 Completed
NCT04436133 2022-05-06
Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)
National Vaccine and Serum Institute, China
Phase 2 Completed
NCT05156541 2021-12-14
ING-HPV-1
SPP Pharmaclon Ltd.
Phase 3 Completed
NCT04083196 2021-11-24
A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years
National Vaccine and Serum Institute, China
Phase 1 Completed
NCT04199260 2021-08-09
PAPILOBS
Procare Health Iberia S.L.
Completed
NCT04002154 2021-02-16
PALOMA
Procare Health Iberia S.L.
Phase NA Completed
NCT02482428 2021-01-05
Efficacy and Tolerability of Topical LFX453 for External Genital Warts
Novartis
Phase 2 Completed
NCT00481767 2020-11-17
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.
GlaxoSmithKline
Phase 3 Completed
NCT00947115 2020-10-30
Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects
GlaxoSmithKline
Phase 3 Completed
NCT01031069 2020-07-21
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
GlaxoSmithKline
Phase 4 Completed
NCT03929172 2020-07-01
A Study of Safety, Tolerability and Immunogenicity of HPV-L2 Vaccine in Healthy Adult Male and Female Subjects
2A Pharma AB
Phase 1 Completed
NCT01381575 2020-06-09
Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls
GlaxoSmithKline
Phase 3 Completed
NCT01627561 2020-04-10
Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old
GlaxoSmithKline
Phase 3 Completed
NCT03546842 2020-02-25
V503-017
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00877877 2020-01-18
Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects.
GlaxoSmithKline
Phase 3 Completed
NCT00586339 2020-01-03
Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females
GlaxoSmithKline
Phase 2 Completed
NCT00637195 2020-01-03
Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)
GlaxoSmithKline
Phase 3 Completed
NCT00250276 2020-01-02
Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.
GlaxoSmithKline
Phase 3 Completed
NCT00294047 2020-01-02
Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older
GlaxoSmithKline
Phase 3 Completed
NCT00359619 2020-01-02
Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine
GlaxoSmithKline
Phase 2 Completed
NCT00423046 2020-01-02
Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age
GlaxoSmithKline
Phase 3 Completed
NCT00231413 2019-12-12
Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.
GlaxoSmithKline
Phase 2 Completed
NCT00196937 2019-12-11
Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18
GlaxoSmithKline
Phase 3 Completed
NCT03158220 2019-11-21
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
Merck Sharp & Dohme LLC
Phase 3 Completed